Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya

Magudha, J.; Ndwiga, L.; Akinyi, M.; Wamae, K.; Osoti, V.; Kandie, R.; Kiplagat, R.; Keitany, K.; Bargul, J. L.; Akala, H. M.; Oyier, L. I. O.

doi:10.1101/2025.09.09.675152

bioRxiv · 10.1101/2025.09.09.675152

Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya

Magudha, J.·Ndwiga, L.·Akinyi, M.·Wamae, K.·Osoti, V.·Kandie, R.·Kiplagat, R.·Keitany, K.·Bargul, J. L.·Akala, H. M.·Oyier, L. I. O.

View original source ↗Export metadata ↓

Abstract

BackgroundHistorically, chloroquine resistance emerged that was driven by mutations in the chloroquine resistance transporter (Pfcrt) gene. This led to the global withdrawal of chloroquine in 1998 and its subsequent replacement with sulfadoxine-pyrimethamine, whose efficacy was compromised by a high prevalence of mutations in the dihydrofolate reductase and the dihydropteroate synthase genes by 2004. Consequently, artemisinin-based combination therapies (ACTs) were introduced in 2006. Since then, thirteen mutations in the kelch 13 (Pfk13) propeller domain have emerged and validated by the World Health Organization (WHO) as markers of partial artemisinin resistance. This study aimed to characterize temporal trends in both established, Pfcrt and Pfk13 and less well-described potential markers, cysteine desulfurase (Pfnfs) and Pfcoronin, using febrile malaria samples collected across diverse regions of Kenya between 2013 and 2022. MethodsThe temporal trend of these markers of resistance were assessed by screening archived P. falciparum positive dried blood spots (DBS). A total of 1,750 DBS samples collected from Therapeutic Efficacy Studies (TES) conducted in: Kwale (2013, n=350), Kisumu (2015, n=314), Busia (2016, n=334), Kisii (2017, n=314), Kwale (2018, n=150), and a hrp2 study conducted Kisii (2022, n=288). Parasite genomic DNA was extracted using the Chelex-saponin method and confirmed by a Pf 18S RT-PCR. Pfk13, Pfcrt, Pfnfs and Pfcoronin PCR amplicons were sequenced using capillary electrophoresis, Illumina Miseq or the Oxford Nanopore (GridION) platform. ResultsThe prevalence of Pfcrt mutations declined over time and no WHO validated Pfk13 mutations associated with artemisinin resistance were detected. However, synonymous substitutions at WHO-validated codons C469C and P553P were identified. In the PfCoronin gene, non-synonymous mutations distinct from those reported in West Africa were observed at high frequencies (>75%). Notably, the Pfnfs-K65Q mutation, previously associated with reduced lumefantrine sensitivity in West Africa, was detected in over 80% of samples. Our findings reveal differences in some antimalarial resistance genetic markers between observations made in The Gambia and Senegal (West Africa) and Kilifi (East Africa). Based on the convenient sample set, there were no WHO validated k13 mutations up until 2022, suggesting continued ACT efficacy in Kenya. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared to West Africa and Southeast Asia.

Explore related subjects

genomics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Magudha, J., Ndwiga, L., Akinyi, M., Wamae, K., Osoti, V., Kandie, R., Kiplagat, R., Keitany, K., Bargul, J. L., Akala, H. M., Oyier, L. I. O.. 2025-09-15. Convenient screening for drug resistance mutations from historical febrile malaria samples across Kenya. https://doi.org/10.1101/2025.09.09.675152

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

RNA isoform-resolved multiplexed sequencing with bioorthogonal barcoding

RNA isoform dysregulation drives disease pathogenesis and is the target of FDA-approved splice-switching therapeutics. However, multiplexed sequencing methods discard splice junction information because only 3' termini are barcoded and counted. Here, we repurpose acylation and click chemistries to conjugate bioorthogonal barcodes (bobcodes) directly onto multiple internal positions along cellular RNAs. Bobcoded RNAs from multiple samples are pooled for multiplexed cDNA synthesis, during which reverse transcriptase switches from each RNA template onto its tethered bobcode with greater than 99% accuracy in species mixing experiments. Bobcode attachment intervals set cDNA insert sizes without a library fragmentation step, and priming with poly(dT) or random hexamers selects between 3'-end counting and full-length isoform capture. A bioorthogonal barcode-sequencing (BOB-seq v0.1) drug screen identifies transcriptome-wide on- and off-target RNA splicing effects and outperforms existing multiplexing RNA sequencing methods in workflow simplicity, sample-to-sample variability, and barcoding accuracy. Bobcodes add isoform resolution to scalable multiplexed RNA sequencing.

genomics↗

bioRxiv2026

Integrative Nanopore and Illumina sequencing reveals age-associated tRNA modification and CCA-tail dynamics in yeast

Aging is characterized by a progressive loss of proteostasis. Transfer RNAs (tRNAs) are essential regulators of translation, yet their dynamics during aging remain poorly understood due to challenges in sequencing highly modified RNAs. Here we present a benchmarked Nanopore direct RNA sequencing (RNA004 chemistry) resource that profiles the Saccharomyces cerevisiae tRNAome during replicative aging at single-molecule resolution. Using in vitro transcribed tRNA controls, we establish modification detection thresholds and validate key findings with orthogonal Illumina sequencing. While overall tRNA abundance remains largely stable, our resource reveals age-associated terminal A cleavage at the 3' CCA tail of mature tRNAs, targeted T-loop and anticodon modification changes, and single-molecule evidence of modification co-occurrence. This dataset provides a resource for exploring tRNA regulation, translation fidelity, and longevity.

genomics↗

bioRxiv2026

A hydrogen-producing mitochondrion in an anaerobic eukaryotrophic rhizarian

Diverse eukaryotes thrive under low oxygen conditions, in part through highly modified mitochondrion-related organelles (MROs) that use alternate metabolic pathways to support ATP production and cofactor recycling. Anaerobic lifestyles have evolved repeatedly across the eukaryotic tree of life, each providing an independent opportunity to understand how eukaryotes adapt to life in low oxygen conditions. Here, we use single-cell transcriptomics to reconstruct the MRO metabolism of PCE SSF, a benthic eukaryotrophic flagellate and the first cultivated representative of Novel Clade 12 (NC12; Rhizaria), an independently anaerobic rhizarian lineage. PCE SSF possesses an anaerobic hydrogen-producing mitochondrion capable of hydrogenosome-type substrate-level phosphorylation. It also retains a nearly complete but likely branched tricarboxylic acid pathway that lacks citrate synthase and malate dehydrogenase. The function of citrate synthase may instead be fulfilled by the typically cytosolic ATP citrate lyase, previously reported in this context only in the anaerobic cercozoan, Brevimastigomonas motovehiculus. Unlike B. motovehiculus, however, PCE SSF retains only Complex II and the NuoE/NuoF subunits of the electron transport chain and lacks a mitochondrial genome. Together, these features indicate an atypical and reduced mitochondrial metabolism, highlighting the diversity of evolutionary solutions to anaerobic energy metabolism in eukaryotes.

genomics↗